Glucosamine now available on prescription

Alateris (glucosamine) is the first prescription-only glucosamine product to receive a licence in the UK for the treatment of mild to moderate osteoarthritis (OA) of the knee.

The efficacy of glucosamine has been assessed in several clinical studies. In two long-term trials, glucosamine was reported to be more effective than placebo in reducing symptoms in patients with mild to moderate OA of the knee. It was also reported to be as effective as ibuprofen in two double-blind randomised four-week studies (n=178 and 200, respectively) in patients with OA of the knee.

Each Alateris tablet contains glucosamine 625mg. The daily dose is two tablets once daily. Relief of symptoms may not be experienced until after several weeks of treatment, and in some cases, even longer. If no relief of symptoms is experienced after two to three months, continued treatment with glucosamine should be re-evaluated.

Further information: Ransom 01462 437615

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregnant woman having an ultrasound scan with a female sonographer

Valproate prescribing: plan for new regulatory measures without delay, instructs MHRA

A National Patient Safety Alert (NatPSA) has been issued...